75 results about "Diabetes mellitus therapy" patented technology

The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors.

The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): (wherein X represents a halogen atom, R 1 represents a hydrogen atom, R 2 represents an alkyl group containing 1 to 7 carbon atoms, R 3 represents -CHO, and R 4 represents -CH 2 -CH=C(CH 3 )-R 0 (wherein R 0 represents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, etc.)), an optical isomer thereof or a pharmaceutically acceptable salt thereof has a high inhibitory effect on dihydroorotic acid dehydrogenase and can be used as an immunosuppressive agent, a therapeutic agent for rheumatism, an anticancer agent, a therapeutic agent for graft rejection, an antiviral agent, an anti- H . pylori agent, a therapeutic agent for diabetes or the like.

The invention provides application of mitochondria-derived polypeptide MOTS-c and a derivative thereof in preparation of a medicine for treating gestational diabetes mellitus (GDM), and belongs to the technical field of biomedicine. The MOTS-c is highly conserved in humans, rodents and various mammals, and it is found that the plasma MOTS-c content of a GDM pregnant woman is obviously reduced; the MOTS-c treatment can reduce pregnancy blood glucose of GDM model mice, improve insulin resistance, improve glucose tolerance, reduce offspring birth weight, protect pancreas islet functions and maintain insulin secretion; and therefore, the mitochondria-derived polypeptide MOTS-c has the potential of preparing medicines for preventing and treating GDM and complications thereof.

The invention discloses application of OGT as a target in preparation of a medicine for treating abnormal secretion of glucagon in diabetes. The medicine is a medicine for inhibiting expression of O-GlcNAc glycosyltransferase OGT, wherein the functional component can be at least one of shRNA, siRNA, dsRNA, miRNA, cDNA, antisense RNA/DNA, a low molecular compound, peptide and an antibody. Studies find that the secretion amount of glucagon can be reduced by knocking out or inhibiting O-GlcNAc glycosyltransferase OGT, meanwhile, withering of islet alpha cells can be promoted, proliferation of the islet alpha cells is inhibited, and O-GlcNAc glycosyltransferase OGT can be used as a target for treating diabetes.

The invention belongs to the technical field of pharmaceutical preparations and preparation methods thereof, and particularly relates to a polypeptide nanoparticle for treating diabetes, a polypeptidenanoparticle microneedle and a preparation method of the polypeptide nanoparticle microneedle. The method comprises the following steps: 1) preparing chitosan nanoparticles entrapped with exenatide;2) preparing a polymer composite microneedle with strong hardness, high solubility and good biocompatibility by a physical crosslinking technology; and 3) freeze-drying the nanoparticles into a powder, and loading the powder into the polymer microneedle to prepare the dry powder drug-loaded microneedle. The exenatide nanoparticle freeze-dried powder is loaded by utilizing holes naturally formed inthe preparation process of the polymer microneedle to prepare the exenatide dry powder microneedle for treating type 2 diabetes. A exenatide chitosan nanoparticle microneedle transdermal patch disclosed by the invention can effectively reduce the risks of strong inflammation and immune system reaction caused by the medicine, so the painless, needleless, transdermal and slow blood glucose-releasing purposes are achieved.

The invention discloses tau protein and application of a gene of the tau protein as a drug target in preparation of a drug for treating diabetes, and relates to the technical field of diabetes treatment. The invention discloses an application of a reagent taking tau protein or tau gene as a target point in preparation of a medicine for preventing or treating diabetes mellitus. Embodiment of the invention creatively shows that tau protein has an important regulation and control effect in insulin secretion, and diabetes mellitus can be treated by targeting the tau protein or the tau gene. The invention provides a new thought and strategy for diabetes treatment and drug research and development or screening.

The invention provides a diabetic patient education and treatment scheme adjustment method and system in the technical field of diabetes management. The method comprises the following steps: step S10, obtaining a user file, a reading habit and a learning progress to generate a user portrait of a diabetic patient; step S20, pushing courses based on the user portrait; s30, examining the diabetic patient based on the course, and adjusting the pushed course; step S40, acquiring complication data, examination data and behavior data, and creating a treatment scheme screening model and a treatment scheme sorting model; s50, the treatment scheme screening model screens a treatment scheme by using the user file, the complication data, the inspection data and the behavior data; and step S60, sorting the treatment schemes by using the treatment scheme sorting model, selecting an optimal treatment scheme, and pushing the optimal treatment scheme to the user terminal. The system and the method have the advantages that the education of the diabetic patient and the dynamic adjustment of the treatment scheme are realized, so that the diabetes treatment effect is greatly improved.

The invention provides an application of CUL4B in treatment of type 2 diabetes mellitus. Research finds that the CUL4B can negatively regulate adipose differentiation, and further research proves thatCul4b knockout mice can be improved in insulin resistance and type 2 diabetes mellitus symptom. In terms of mechanism, insulin signaling pathways in AKO mice are found to be more sensitive, and adipocytes are found to absorb glucose more easily. Meanwhile, the infiltration of macrophages in adipose tissues of the AKO mice is obviously reduced. Therefore, the CUL4B can be used as a potential drugtarget, the protein activity of the CUL4B can be inhibited to reduce the blood sugar and improve the symptom of the type 2 diabetes mellitus, and the CUL4B has good practical application value.

The invention discloses a preparation process of a medicine for treating diabetes mellitus, which comprises the following specific steps: weighing various medicinal materials; the invention relates to the technical field of medicines for treating diabetes mellitus, and relates to the technical field of medicines for treating diabetes mellitus. The medicines comprise 10-35g of codonopsis pilosula, 5-30g of raw bighead atractylodes rhizome, 10-35g of poria cocos, 2-10g of coptis chinensis, 2-10g of dried ginger, 8-22g of cassia twig, 32-50g of angelica sinensis, 3-15g of medicated leaven, 4-15g of fructus amomi, 5-20g of white paeony root, 15-40g of radix astragali preparata, 5-30g of red ginseng, 23-35g of golden cypress, 17-35g of pericarpium citri reticulatae, 4-20g of pseudo-ginseng, 4-20g of amber, 4-20g of crude dragon bone, 3-20g of raw oyster shell and the like. According to the preparation technology of the medicine for treating the diabetes, crushed medicinal materials enter the discharging barrel, gravity sensors are arranged on the top of an opening and closing plate and in the opening and closing plate, and according to the total weight of the added medicinal materials, when the gravity sensors detect that the weight of medicine powder is close to the total weight of the added medicinal materials, the opening and closing plate is controlled to be opened; and the medicine powder can fall into the collecting box, so that the device automatically detects the crushing process and timely removes the internal medicine powder.

The present invention relates to novel methods and therapies for treating, preventing or delaying the onset of type 1 diabetes. In one aspect, the invention provides a method of preventing, delaying the onset of, or delaying the progression of, type 1 diabetes (T1D) in an individual, the method comprising providing in the individual an anti-inflammatory compound; and a pancreatic autoantigen or a derivative or variant thereof; thereby preventing, delaying the onset of, or delaying the progression of, T1D in the individual.

The present invention provides treatment of diabetes mellitus targeting abnormal stem cells in combination with migration of stem cells. In one embodiment, the invention provides treatment of diabetes and/or diseases, disorders and/or symptoms associated with diabetes targeting abnormal stem cells in combination with migration of stem cells. In one embodiment, the present invention provides the diagnosis of diabetes and/or a disease, disorder and/or symptom associated with diabetes, or a risk thereof, metered by migration and/or residual of abnormal stem cells.